August 17, 2012

High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Immunosuppressive therapies used in lung transplant recipients increase the risk of cutaneous squamous cell carcinoma (SCC). This retrospective study hypothesized that voriconazole, used for treatment of invasive fungal infections and known to have phototoxic side effects, may be an additional risk factor for SCC in lung transplant recipients. Cumulative exposure to voriconazole was calculated for 327 adult lung transplant recipients between 1991 and 2010 and correlated with incidence of SCC. Voriconazole exposure was associated with a 2.6-fold increased risk of SCC, and the effect was dose dependent.

Lung Transplantation

Tags: , ,